Author: Surabotsophon, Manoon; Klaiâ€On, Yingyot; Thanachartwet, Vipa; Khunapornphairote, Sirote; Chamnanchanunt, Supat; Racharak, Theerapat; Laisuan, Wannada; Sahassananda, Duangjai; Hapunna, Samlee; Jinapuk, Somjit; Leelasetakul, Suthee; Desakorn, Varunee
Title: Tocilizumab for treating severe COVIDâ€19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series Cord-id: ank6t9al Document date: 2020_10_13
ID: ank6t9al
Snippet: Three patients diagnosed with severe COVIDâ€19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received tocilizumab when the disease progressed to acute respiratory distress syndrome, and died.
Document: Three patients diagnosed with severe COVIDâ€19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received tocilizumab when the disease progressed to acute respiratory distress syndrome, and died.
Search related documents:
Co phrase search for related documents- absolute neutrophil count and acute aki kidney injury: 1
Co phrase search for related documents, hyperlinks ordered by date